News Wire

Positive results have been reported from a phase 2b study of an investigational oral insulin capsule (ORMD-0801) in patients with type-2 diabetes (T2D). The study’s primary objective––a significant reduction of weighted mean night-time glucose––was successfully achieved.

The independent data monitoring committee for a pivotal phase 3 breast-cancer trial of ribociclib (LEE011, Novartis), a cyclin-dependent kinase inhibitor, has recommended stopping the trial early after results of a preplanned interim analysis showed that the study had met the primary endpoint of a clinically meaningful improvement in progression-free survival (PFS).

Researchers posing as patients with skin problems sought help from direct-to-consumer (DTC) telemedicine websites––with troubling results, according to a study published in JAMA Dermatology.

Benralizumab (AstraZeneca/MedImmune), an investigational anti-eosinophil monoclonal antibody, was well tolerated and achieved the primary endpoint in two pivotal phase 3 trials, demonstrating significant reductions in the annual asthma exacerbation rate compared with placebo.

Valeant Pharmaceuticals International, Inc., has announced that it will make available to all hospitals in the United States an enhanced rebate program to reduce the prices of Nitropress (nitroprusside) and Isuprel (isoproterenol).

Using projections based on data from the American Board of Thoracic Surgery (ABTS), investigators at the Ohio State University have warned public health officials that the United States is heading toward a crisis in being able to provide adequate cardiothoracic surgical services to meet future demand.

After Los Angeles was hit by “super bug” outbreaks last year involving hard-to-clean medical scopes, state health inspectors descended on two of the city’s largest hospitals and found numerous safety violations that appeared to put more patients at risk, according to an article in the Los Angeles Times.

U.S. states and territories can now apply to the Centers for Disease Control and Prevention (CDC) for funds to fight the Zika virus locally. More than $85 million in redirected funds identified by the Department of Health and Human Services is being made available to support efforts to protect U.S.

GlobalData, a global commercial intelligence provider, expects the Huntington’s disease (HD) market to show a compound annual growth rate of 23.9% in the United States between 2014 and 2024.

The FDA has approved lenvatinib (Lenvima, Eisia, Inc.), a multiple receptor tyrosine kinase (RTK) inhibitor, in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) who were previously treated with an antiangiogenic therapy.

Novo Nordisk has announced the submission to the FDA of a biologics license application for the approval of nonacog beta pegol, a long-acting glycopegylated recombinant factor IX developed for patients with hemophilia B.

The FDA is advising health care providers that the serious adverse effects associated with fluoroquinolone antibacterial drugs generally outweigh the benefits for patients with sinusitis, bronchitis, and uncomplicated urinary tract infections who have other treatment options.

A new experimental and clinical study from Lund University in Sweden shows that the sleep hormone melatonin impairs insulin secretion in people with a common gene variant.

“This could explain why the risk of type-2 diabetes is greater among, for instance, overnight workers or people with sleeping disorders,” says Professor Hindrik Mulder, who is responsible for the study.

The rate of uninsured Americans under the age of 65 fell in three out of four counties from 2013 to 2014 and rose in just a single county, the U.S. Census Bureau says.

A new report assesses how the nation fared against an ambitious challenge goal set by the American Cancer Society in 1996—reducing the cancer death rate by 50% over the 25 years ending in 2015.  The report finds areas where progress was substantial and areas where it was not.